Recombinant SV2A antibody (Cytoplasmic Domain, N-Term)

Catalog No. ABIN8093502

The Mouse Monoclonal anti-SV2A antibody (Clone r15E11) (ABIN8093502) specifically detects SV2A in IHC. The antibody is reactive with Human samples.

Quick Overview for Recombinant SV2A antibody (Cytoplasmic Domain, N-Term) (ABIN8093502)

Target: SV2A (Synaptic Vesicle Glycoprotein 2A (SV2A))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This SV2A antibody is un-conjugated

Application: Immunohistochemistry (IHC)

Grade: Carrier-free

Clone: R15E11

Product Details anti-SV2A Antibody

Binding Specificity: Cytoplasmic Domain, N-Term

Purpose: SV2A Antibody / Synaptic vesicle glycoprotein 2A (azide and preservative free)

Immunogen: Prokaryotic recombinant protein corresponding to the N-terminal cytoplasmic domain of the human synaptic vesicle 2A molecule which shares some regions of homology with the SV2B molecule was used as the immunogen for the SV2 Protein/Synaptic Vesicle Protein antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: 1. Optimal dilution of the SV2 Protein/Synaptic Vesicle Protein antibody should be determined by the researcher.

2. This SV2 Protein/Synaptic Vesicle Protein antibody is recombinantly produced by expression in CHO cells.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C,-80 °C

Storage Comment: SV2 Protein/Synaptic Vesicle Protein antibody with sodium azide - store at 2 to 8oC, antibody without sodium azide - store at -20 to -80oC.

Target Details for SV2A

Target: SV2A (Synaptic Vesicle Glycoprotein 2A (SV2A))

Alternative Name: SV2A

Background: SV2 Protein antibody recognizes Synaptic vesicle protein 2A, commonly referred to as SV2A, a multi-pass transmembrane protein encoded by the SV2A gene that localizes to synaptic vesicle membranes within presynaptic nerve terminals. SV2 Protein Antibody is developed to detect endogenous Synaptic vesicle protein in research applications focused on neuronal communication and vesicle trafficking. SV2A is widely expressed throughout the central nervous system in both excitatory and inhibitory neurons, where it contributes to regulated neurotransmitter release and synaptic vesicle cycling.

Synaptic vesicle protein 2A is a member of the SV2 family, which includes SV2A, SV2B, and SV2C. The protein spans the vesicle membrane multiple times and is enriched in presynaptic terminals, where it modulates vesicle priming, exocytosis efficiency, and calcium-dependent neurotransmitter release. Although its precise molecular mechanism remains under investigation, SV2A is recognized as a critical regulator of synaptic strength and vesicular release probability.

The SV2A gene is located on chromosome 1q21.3 and is highly enriched in brain regions with dense synaptic connectivity, including cortex, hippocampus, and cerebellum. In addition to neuronal tissues, Synaptic vesicle protein 2A is detected at lower levels in certain endocrine and neuroendocrine cells, consistent with its broader role in regulated secretory pathways. Altered SV2A expression has been associated with epilepsy and other neurologic disorders. Notably, Synaptic vesicle protein 2A serves as the molecular binding target of the antiepileptic drug levetiracetam, highlighting its translational importance in seizure research.

Because SV2A is consistently present in presynaptic terminals, it is widely used as a marker of synaptic density and neuronal integrity in studies of neurodevelopment, neurodegeneration, and brain injury. Changes in Synaptic vesicle protein levels may reflect synaptic remodeling or loss in experimental models.

Clone r15E11 is a recombinant mouse monoclonal antibody that recognizes Synaptic vesicle protein 2A and supports studies of synaptic vesicle biology, neurotransmitter release mechanisms, and neuronal network organization.

UniProt: Q7L0J3